Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG006 vs Chemotherapy in Advanced Neuroendocrine Carcinoma
NCT07595913Phase 3Not yet recruiting
- Sponsor
- Zelgen
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alveltamig in neuroendocrine carcinoma (NEC) (2 arms), sponsored by Zelgen. Primary endpoint: Overall Survival at 4 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
alveltamig
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07595913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595913.